Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Nuvation Bio (NUVB) Research & Development (2023 - 2025)

Nuvation Bio (NUVB) has disclosed Research & Development for 3 consecutive years, with $34.3 million as the latest value for Q4 2025.

  • On a quarterly basis, Research & Development rose 17.06% to $34.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $115.1 million, a 16.13% increase, with the full-year FY2025 number at $115.1 million, up 16.13% from a year prior.
  • Research & Development was $34.3 million for Q4 2025 at Nuvation Bio, up from $28.8 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $34.3 million in Q4 2025 to a low of $12.8 million in Q1 2024.
  • A 3-year average of $23.8 million and a median of $26.0 million in 2025 define the central range for Research & Development.
  • Peak YoY movement for Research & Development: tumbled 31.64% in 2024, then surged 91.57% in 2025.
  • Nuvation Bio's Research & Development stood at $15.4 million in 2023, then skyrocketed by 90.86% to $29.3 million in 2024, then increased by 17.06% to $34.3 million in 2025.
  • Per Business Quant, the three most recent readings for NUVB's Research & Development are $34.3 million (Q4 2025), $28.8 million (Q3 2025), and $27.4 million (Q2 2025).